vs
波士顿科学（BSX）与皇家加勒比集团（RCL）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是皇家加勒比集团的1.2倍（$5.2B vs $4.3B），波士顿科学净利率更高（25.7% vs 17.7%，领先8.1%），皇家加勒比集团同比增速更快（13.3% vs 11.6%），过去两年波士顿科学的营收复合增速更高（12.4% vs 6.9%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
皇家加勒比集团前身为皇家加勒比邮轮有限公司，是仅次于嘉年华公司的全球第二大邮轮运营商。集团总部位于美国佛罗里达州迈阿密，在利比里亚注册，目前全资拥有皇家加勒比国际游轮、名人邮轮、银海邮轮三大品牌，还持有途易邮轮50%的股份。
BSX vs RCL — 直观对比
营收规模更大
BSX
是对方的1.2倍
$4.3B
营收增速更快
RCL
高出1.7%
11.6%
净利率更高
BSX
高出8.1%
17.7%
两年增速更快
BSX
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $4.3B |
| 净利润 | $1.3B | $753.0M |
| 毛利率 | 69.5% | 47.4% |
| 营业利润率 | — | 21.9% |
| 净利率 | 25.7% | 17.7% |
| 营收同比 | 11.6% | 13.3% |
| 净利润同比 | 99.0% | 36.4% |
| 每股收益（稀释后） | $0.90 | $2.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXRCL
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $4.3B | ||
| Q3 25 | $5.1B | $5.1B | ||
| Q2 25 | $5.1B | $4.5B | ||
| Q1 25 | $4.7B | $4.0B | ||
| Q4 24 | $4.6B | $3.8B | ||
| Q3 24 | $4.2B | $4.9B | ||
| Q2 24 | $4.1B | $4.1B |
净利润BSXRCL
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $753.0M | ||
| Q3 25 | $755.0M | $1.6B | ||
| Q2 25 | $795.0M | $1.2B | ||
| Q1 25 | $672.0M | $730.0M | ||
| Q4 24 | $563.0M | $552.0M | ||
| Q3 24 | $468.0M | $1.1B | ||
| Q2 24 | $322.0M | $854.0M |
毛利率BSXRCL
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 47.4% | ||
| Q3 25 | 69.9% | 51.8% | ||
| Q2 25 | 67.7% | 49.7% | ||
| Q1 25 | 68.8% | 48.0% | ||
| Q4 24 | 67.8% | 45.4% | ||
| Q3 24 | 68.8% | 51.1% | ||
| Q2 24 | 69.2% | 47.6% |
营业利润率BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 21.9% | ||
| Q3 25 | 20.7% | 33.1% | ||
| Q2 25 | 16.2% | 29.3% | ||
| Q1 25 | 19.8% | 23.6% | ||
| Q4 24 | 14.8% | 16.6% | ||
| Q3 24 | 17.4% | 33.4% | ||
| Q2 24 | 12.6% | 26.7% |
净利率BSXRCL
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 17.7% | ||
| Q3 25 | 14.9% | 30.6% | ||
| Q2 25 | 15.7% | 26.7% | ||
| Q1 25 | 14.4% | 18.3% | ||
| Q4 24 | 12.3% | 14.7% | ||
| Q3 24 | 11.1% | 22.7% | ||
| Q2 24 | 7.8% | 20.8% |
每股收益（稀释后）BSXRCL
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $2.76 | ||
| Q3 25 | $0.51 | $5.74 | ||
| Q2 25 | $0.53 | $4.41 | ||
| Q1 25 | $0.45 | $2.70 | ||
| Q4 24 | $0.38 | $2.27 | ||
| Q3 24 | $0.32 | $4.21 | ||
| Q2 24 | $0.22 | $3.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $825.0M |
| 总债务越低越好 | — | $18.2B |
| 股东权益账面价值 | — | $10.0B |
| 总资产 | — | $41.6B |
| 负债/权益比越低杠杆越低 | — | 1.81× |
8季度趋势，按日历期对齐
现金及短期投资BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $825.0M | ||
| Q3 25 | $1.3B | $432.0M | ||
| Q2 25 | $534.0M | $735.0M | ||
| Q1 25 | $725.0M | $386.0M | ||
| Q4 24 | $414.0M | $388.0M | ||
| Q3 24 | $2.5B | $418.0M | ||
| Q2 24 | $2.9B | $391.0M |
总债务BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $18.2B | ||
| Q3 25 | $11.1B | $17.2B | ||
| Q2 25 | $11.1B | $17.6B | ||
| Q1 25 | $10.5B | $18.0B | ||
| Q4 24 | $9.0B | $18.5B | ||
| Q3 24 | $9.2B | $19.0B | ||
| Q2 24 | $9.0B | $19.8B |
股东权益BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $10.0B | ||
| Q3 25 | $23.4B | $10.1B | ||
| Q2 25 | $22.4B | $9.2B | ||
| Q1 25 | $22.2B | $8.0B | ||
| Q4 24 | $21.8B | $7.6B | ||
| Q3 24 | $20.7B | $7.0B | ||
| Q2 24 | $20.4B | $6.0B |
总资产BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $41.6B | ||
| Q3 25 | $42.7B | $40.1B | ||
| Q2 25 | $41.6B | $38.5B | ||
| Q1 25 | $40.1B | $37.5B | ||
| Q4 24 | $39.4B | $37.1B | ||
| Q3 24 | $38.1B | $37.1B | ||
| Q2 24 | $37.1B | $37.0B |
负债/权益比BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | 1.81× | ||
| Q3 25 | 0.48× | 1.70× | ||
| Q2 25 | 0.50× | 1.92× | ||
| Q1 25 | 0.47× | 2.26× | ||
| Q4 24 | 0.41× | 2.44× | ||
| Q3 24 | 0.45× | 2.69× | ||
| Q2 24 | 0.44× | 3.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $1.6B |
| 自由现金流经营现金流 - 资本支出 | — | $116.0M |
| 自由现金流率自由现金流/营收 | — | 2.7% |
| 资本支出强度资本支出/营收 | — | 35.4% |
| 现金转化率经营现金流/净利润 | — | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | $1.2B |
8季度趋势，按日历期对齐
经营现金流BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $541.0M | $1.6B | ||
| Q4 24 | $1.5B | $1.5B | ||
| Q3 24 | $1.0B | $897.0M | ||
| Q2 24 | $813.0M | $1.6B |
自由现金流BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $116.0M | ||
| Q3 25 | $1.2B | $-989.0M | ||
| Q2 25 | $1.1B | $910.0M | ||
| Q1 25 | $354.0M | $1.2B | ||
| Q4 24 | $1.2B | $915.0M | ||
| Q3 24 | $823.0M | $563.0M | ||
| Q2 24 | $658.0M | $-567.0M |
自由现金流率BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 2.7% | ||
| Q3 25 | 22.9% | -19.2% | ||
| Q2 25 | 22.3% | 20.1% | ||
| Q1 25 | 7.6% | 30.0% | ||
| Q4 24 | 25.8% | 24.3% | ||
| Q3 24 | 19.6% | 11.5% | ||
| Q2 24 | 16.0% | -13.8% |
资本支出强度BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 35.4% | ||
| Q3 25 | 3.6% | 47.8% | ||
| Q2 25 | 3.1% | 18.4% | ||
| Q1 25 | 4.0% | 10.7% | ||
| Q4 24 | 6.1% | 14.7% | ||
| Q3 24 | 4.3% | 6.8% | ||
| Q2 24 | 3.8% | 52.1% |
现金转化率BSXRCL
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 2.16× | ||
| Q3 25 | 1.78× | 0.93× | ||
| Q2 25 | 1.62× | 1.44× | ||
| Q1 25 | 0.81× | 2.23× | ||
| Q4 24 | 2.59× | 2.66× | ||
| Q3 24 | 2.14× | 0.81× | ||
| Q2 24 | 2.52× | 1.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
RCL
| Passenger | $2.9B | 69% |
| Other | $1.3B | 31% |
